SNY Sanofi

44.92
+0.51  (+1%)
Previous Close 44.41
Open 44.74
Price To Book 1.79
Market Cap 112,491,675,347
Shares 2,504,267,038
Volume 993,654
Short Ratio
Av. Daily Volume 1,359,418

NewsSee all news

  1. Happify Health and Sanofi Sign Global Agreement to Bring Prescription Digital Mental Health Therapeutics to Individuals with Multiple Sclerosis

    NEW YORK, Sept. 17, 2019 /PRNewswire/ -- Happify Health, a global leader in mental health technology, today announced it signed an agreement with global biopharmaceutical company Sanofi (NASDAQ:SNY) to advance the

  2. Hagens Berman: National Class-Action Lawsuit Accuses Sanofi of Concealing Zantac Cancer Risk

    Law firm urges Zantac users to find out their rights against drug maker who knowingly sold potentially carcinogenic medication A newly filed class-action lawsuit accuses international drug maker Sanofi of intentionally

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 4Q 2019.
Sutimlimab (BIVV009) - Cardinal
Cold agglutinin disease
Phase 3 data due 4Q 2019.
Sutimlimab (BIVV009) - Cadenza
Cold agglutinin disease
FDA Approval announced September 28, 2018.
Cemiplimab
Cutaneous squamous cell carcinoma
Approval announced December 11, 2017.
Admelog (insulin lispro injection)
Diabetes
sBLA Approval announced April 25, 2017.
Praluent (alirocumab)
High low-density lipoprotein (LDL) cholesterol
Phase 3 trial commenced 4Q 2017. Data due 2020.
Efpeglenatide
Type 2 diabetes
Phase 3 data met endpoints - August 6, 2019.
Dupixent (dupilumab)
Atopic dermatitis 6-11 year-olds
FDA approval announced March 11, 2019.
Dupixent (dupilumab)
Atopic dermatitis 12-17 year-olds
FDA approval announced April 26, 2019.
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
PDUFA date April 30, 2020.
Isatuximab
Refractory Multiple Myeloma
Phase 3 data due 2Q 2020.
Avalglucosidase alfa (NeoGAA) - COMET
Pompe disease
FDA approval announced October 19, 2018.
Dupixent (dupilumab)
Asthma
Pivotal Phase 2/3 trial ongoing.
REGN2810
Cutaneous squamous cell carcinoma
Phase 3 enrolling. Data due 2021.
Cemiplimab
Non-small cell lung cancer (NSCLC)
Phase 3 data due 1Q 2020.
Olipudase alfa
Acid sphingomyelinase deficiency (ASMD)
Data due 2020.
Cemiplimab
Basal cell carcinoma
CRL October 28, 2016. Resubmitted with FDA Approval announced May 22, 2017.
Sarilumab
Rheumatoid arthritis
Phase 3 enrollment commenced 2Q 2017. Data due 2021.
Dupixent (dupilumab)
Asthma - 6-11 year-olds
FDA Approval announced June 26, 2019.
Dupixent (dupilumab)
Nasal polyps
Phase 2 trial to commence 2018.
Dupixent (dupilumab)
Peanut Allergy
Phase 3 trial commenced September 2018.
Dupixent (dupilumab)
Eosinophilic esophagitis
Approved under priority review - March 28, 2017.
Dupixent (dupilumab)
Atopic dermatitis
FDA Approval announced August 10, 2018.
Patisiran
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 3 first read-out expected 2H 2019
Fitusiran (ATLAS)
Hemophilia
Approved January 23, 2019.
Fluzone Quadrivalent (Influenza Vaccine)
Influenza A - children 6-35 months of age.
FDA approval announced May 1, 2019.
Dengvaxia
Dengue
FDA Approval announced February 6, 2019.
Caplacizumab
Acquired thrombotic thrombocytopenic purpura (aTTP)
Phase 2 data due 4Q 2019.
SAR440340
Chronic Obstructive Pulmonary Disease (COPD)
Phase 2 data June 21, 2019 met primary endpoint vs placebo. No increased benefit compared to Dupixent.
SAR440340 (REGN3500)
Asthma
Phase 3 data due 1Q 2020.
Isatuximab - IKEMA
Refractory Multiple Myeloma
Phase 1 data due 4Q 2019.
Sutimlimab (BIVV009)
Immune Thrombocytopenic Purpura
PDUFA date April 25, 2020.
MenQuadfi
Meningococcal meningitis

Latest News

  1. Happify Health and Sanofi Sign Global Agreement to Bring Prescription Digital Mental Health Therapeutics to Individuals with Multiple Sclerosis

    NEW YORK, Sept. 17, 2019 /PRNewswire/ -- Happify Health, a global leader in mental health technology, today announced it signed an agreement with global biopharmaceutical company Sanofi (NASDAQ:SNY) to advance the

  2. Hagens Berman: National Class-Action Lawsuit Accuses Sanofi of Concealing Zantac Cancer Risk

    Law firm urges Zantac users to find out their rights against drug maker who knowingly sold potentially carcinogenic medication A newly filed class-action lawsuit accuses international drug maker Sanofi of intentionally